Aim: To describe the demographic and clinical characteristics of patients with Charcot neuro-osteoarthropathy (CNO) and to examine for differences between participants with Type 1 diabetes mellitus (DM) (T1DM) and Type 2 diabetes mellitus (T2DM). Materials and Methods: Multicenter observational study in eight diabetic foot clinics in six countries between January 1, 1996, and December 31, 2022. Demographic, clinical, and laboratory parameters were obtained from the medical records. Analyses were performed using parametric or nonparametric statistical tests for variables with normally or nonnormally distributed values, respectively. Comparisons of the qualitative data were performed using the chi-square test. Results: Seven hundred seventy-four patients with DM and CNO were included. The mean age at diagnosis of CNO was 54.5 ± 11.7 years, and the median (interquartile range (IQR)) diabetes duration at diagnosis of CNO was 15 (10-22) years. Among participants, 71.8% (n = 546) were male and 83.2% (n = 634) had T2DM. Neuropathy was present in 91.7% (n = 688), retinopathy in 60.2% (n = 452), and nephropathy in 45.2% (n = 337). Subjects with T1DM, compared to T2DM, were diagnosed with CNO at a younger age (46.9 ± 11.0 vs. 57.9 ± 10.2 years, p < 0.001), had longer diabetes duration (median value (IQR): 29.0 (21.0-38.0) vs. 14.0 (8.0-20.0) years, p < 0.001), and had more often microvascular complications (neuropathy, 95.2% in T1DM vs. 87.4% in T2DM, p = 0.006; retinopathy, 83.3% vs. 55.4%, p < 0.001; and nephropathy 67.5% vs. 40.5%, p < 0.001). Conclusions: CNO is predominant in males, occurs in long-standing DM, and is often accompanied by microvascular complications. People with T1DM, compared to those with T2DM, are affected at a younger age, have longer diabetes duration, and have more often microvascular complications.

1st Department of Propaedeutic Internal Medicine Medical School National and Kapodistrian University of Athens Laiko General Hospital Athens Greece

Department of Diabetes and Endocrinology Tameside and Glossop Integrated Care NHS Foundation Trust Ashton Under Lyne and University of Manchester and Manchester Metropolitan University Manchester UK

Department of Endocrinology Medical University of Sofia Sofia Bulgaria

Diabetes and Endocrinology Lancashire Teaching Hospitals NHS Foundation Trust Chorley UK

Diabetes and Endocrinology Post Graduate Institute of Medical Education and Research Chandigarh India

Diabetes and Endocrinology University Hospitals of Leicester NHS Trust Leicester UK

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

UTRGV School of Podiatric Medicine Department of Podiatric Medicine Surgery and Biomechanics Harlingen Texas USA

Zobrazit více v PubMed

Wukich D. K., Schaper N. C., Gooday C., et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023) Diabetes/Metabolism Research and Reviews . 2024;40(3) doi: 10.1002/dmrr.3646.e3646 PubMed DOI

Feldman E. L., Callaghan B. C., Pop-Busui R., et al. Diabetic neuropathy. Nature Reviews Disease Primers . 2019;5(1):p. 41. doi: 10.1038/s41572-019-0092-1. PubMed DOI

Rogers L. C., Frykberg R. G., Armstrong D. G., et al. The Charcot foot in diabetes. Diabetes Care . 2011;34(9):2123–2129. doi: 10.2337/dc11-0844. PubMed DOI PMC

Svendsen O. L., Rabe O. C., Winther-Jensen M., Allin K. H. How common is the rare Charcot foot in patients with diabetes? Diabetes Care . 2021;44(4):e62–e63. doi: 10.2337/dc20-2590. PubMed DOI

Metcalf L., Musgrove M., Bentley J., et al. Prevalence of active Charcot disease in the East Midlands of England. Diabetic Medicine . 2018;35(10):1371–1374. doi: 10.1111/dme.13679. PubMed DOI

Greco T., Mascio A., Comisi C., et al. RANKL-RANK-OPG pathway in Charcot diabetic foot: pathophysiology and clinical-therapeutic implications. International Journal of Molecular Sciences . 2023;24(3):p. 3014. doi: 10.3390/ijms24033014. PubMed DOI PMC

Korst G. S., Ratliff H. T., Torian J., Jimoh R. O., Jupiter D. C. Delayed diagnosis of Charcot foot: a systematic review. The Journal of Foot and Ankle Surgery . 2022;61(5):1109–1113. doi: 10.1053/j.jfas.2022.01.008. PubMed DOI

Julien C. A., Ha Van G., M'Bemba J., et al. Real-world treatment patterns and diagnosis of Charcot foot in Franco-Belgian diabetic foot expert centers (the EPiChar study) Acta Diabetologica . 2023;60(9):1209–1218. doi: 10.1007/s00592-023-02101-3. PubMed DOI

Chaudhary S., Bhansali A., Rastogi A. Mortality in Asian Indians with Charcot's neuroarthropathy: a nested cohort prospective study. Acta Diabetologica . 2019;56(12):1259–1264. doi: 10.1007/s00592-019-01376-9. PubMed DOI

Raspovic K. M., Schaper N. C., Gooday C., et al. Diagnosis and treatment of active charcot neuro-osteoarthropathy in persons with diabetes mellitus: a systematic review. Diabetes/Metabolism Research and Reviews . 2024;40(3) doi: 10.1002/dmrr.3653.e3653 PubMed DOI

Griffiths D. A., Kaminski M. R. Duration of total contact casting for resolution of acute Charcot foot: a retrospective cohort study. Journal of Foot and Ankle Research . 2021;14(1):p. 44. doi: 10.1186/s13047-021-00477-5. PubMed DOI PMC

Game F. L., Catlow R., Jones G. R., et al. Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia . 2012;55(1):32–35. doi: 10.1007/s00125-011-2354-7. PubMed DOI

Armstrong D. G., Todd W. F., Lavery L. A., Harkless L. B., Bushman T. R. The natural history of acute Charcot’s arthropathy in a diabetic foot specialty clinic. Diabetic Medicine . 1997;14(5):357–363. doi: 10.1002/(SICI)1096-9136(199705)14:5<357::AID-DIA341>3.0.CO;2-8. PubMed DOI

Christensen T. M., Gade-Rasmussen B., Pedersen L. W., Hommel E., Holstein P. E., Svendsen O. L. Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker. Journal of Diabetes and its Complications . 2012;26(5):430–434. doi: 10.1016/j.jdiacomp.2012.05.006. PubMed DOI

Gratwohl V., Jentzsch T., Schoni M., et al. Long-term follow-up of conservative treatment of Charcot feet. Archives of Orthopaedic and Trauma Surgery . 2022;142(10):2553–2566. doi: 10.1007/s00402-021-03881-5. PubMed DOI PMC

Osterhoff G., Boni T., Berli M. Recurrence of acute Charcot neuropathic osteoarthropathy after conservative treatment. Foot & Ankle International . 2013;34(3):359–364. doi: 10.1177/1071100712464957. PubMed DOI

Fabrin J., Larsen K., Holstein P. E. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care . 2000;23(6):796–800. doi: 10.2337/diacare.23.6.796. PubMed DOI

Ergen F. B., Sanverdi S. E., Oznur A. Charcot foot in diabetes and an update on imaging. Diabetic Foot & Ankle . 2013;4(1) doi: 10.3402/dfa.v4i0.21884. PubMed DOI PMC

Bariteau J. T., Tenenbaum S., Rabinovich A., Brodsky J. W. Charcot arthropathy of the foot and ankle in patients with idiopathic neuropathy. Foot & Ankle International . 2014;35(10):996–1001. doi: 10.1177/1071100714543649. PubMed DOI

Young M. J., Boulton A. J., MacLeod A. F., Williams D. R., Sonksen P. H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia . 1993;36(2):150–154. doi: 10.1007/BF00400697. PubMed DOI

Pop-Busui R., Boulton A. J., Feldman E. L., et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care . 2017;40(1):136–154. doi: 10.2337/dc16-2042. PubMed DOI PMC

Inker L. A., Eneanya N. D., Coresh J., et al. New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine . 2021;385(19):1737–1749. doi: 10.1056/NEJMoa2102953. PubMed DOI PMC

American Diabetes A. Peripheral arterial disease in people with diabetes. Diabetes Care . 2003;26(12):3333–3341. doi: 10.2337/diacare.26.12.3333. PubMed DOI

van Baal J., Hubbard R., Game F., Jeffcoate W. Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care . 2010;33(5):1086–1089. doi: 10.2337/dc09-1428. PubMed DOI PMC

Tsatsaris G., Rajamand Ekberg N., Fall T., Catrina S. B. Risk factors for Charcot foot development in individuals with diabetes mellitus. Diabetologia . 2024;67(12):2702–2710. doi: 10.1007/s00125-024-06271-9. PubMed DOI PMC

O'Loughlin A., Kellegher E., McCusker C., Canavan R. Diabetic charcot neuroarthropathy: prevalence, demographics and outcome in a regional referral centre. Irish Journal of Medical Science . 2017;186(1):151–156. doi: 10.1007/s11845-016-1508-5. PubMed DOI

Magliano D. J., Boyko E. J. IDF Diabetes Atlas . Brussels: International Diabetes Federation; 2021. PubMed

Salini D., Harish K., Minnie P., et al. Prevalence of Charcot arthropathy in Type 2 diabetes patients aged over 50 years with severe peripheral neuropathy: a retrospective study in a tertiary care South Indian hospital. Indian Journal of Endocrinology and Metabolism . 2018;22(1):107–111. doi: 10.4103/ijem.IJEM_257_17. PubMed DOI PMC

Gale E. A., Gillespie K. M. Diabetes and gender. Diabetologia . 2001;44(1):3–15. doi: 10.1007/s001250051573. PubMed DOI

Petrova N. L., Foster A. V., Edmonds M. E. Difference in presentation of Charcot osteoarthropathy in Type 1 compared with Type 2 diabetes. Diabetes Care . 2004;27(5):1235–1236. doi: 10.2337/diacare.27.5.1235-a. PubMed DOI

Harris M. I., Klein R., Welborn T. A., Knuiman M. W. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care . 1992;15(7):815–819. doi: 10.2337/diacare.15.7.815. PubMed DOI

Stuck R. M., Sohn M. W., Budiman-Mak E., Lee T. A., Weiss K. B. Charcot arthropathy risk elevation in the obese diabetic population. The American Journal of Medicine . 2008;121(11):1008–1014. doi: 10.1016/j.amjmed.2008.06.038. PubMed DOI

Ross A. J., Mendicino R. W., Catanzariti A. R. Role of body mass index in acute Charcot neuroarthropathy. The Journal of Foot and Ankle Surgery . 2013;52(1):6–8. doi: 10.1053/j.jfas.2012.10.003. PubMed DOI

Callaghan B. C., Reynolds E., Banerjee M., Chant E., Villegas-Umana E., Feldman E. L. Central obesity is associated with neuropathy in the severely obese. Mayo Clinic Proceedings . 2020;95(7):1342–1353. doi: 10.1016/j.mayocp.2020.03.025. PubMed DOI PMC

Andersen S. T., Witte D. R., Dalsgaard E. M., et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected Type 2 diabetes followed for 13 years: ADDITION-Denmark. Diabetes Care . 2018;41(5):1068–1075. doi: 10.2337/dc17-2062. PubMed DOI

Lim J. Z. M., Burgess J., Ooi C. G., et al. The peripheral neuropathy prevalence and characteristics are comparable in people with obesity and long-duration Type 1 diabetes. Advances in Therapy . 2022;39(9):4218–4229. doi: 10.1007/s12325-022-02208-z. PubMed DOI PMC

Baliunas D. O., Taylor B. J., Irving H., et al. Alcohol as a risk factor for Type 2 diabetes: a systematic review and meta-analysis. Diabetes Care . 2009;32(11):2123–2132. doi: 10.2337/dc09-0227. PubMed DOI PMC

Mellion M., Gilchrist J. M., de la Monte S. Alcohol-related peripheral neuropathy: nutritional, toxic, or both? Muscle & Nerve . 2011;43(3):309–316. doi: 10.1002/mus.21946. PubMed DOI PMC

Arapostathi C., Tentolouris N., Jude E. B. Charcot foot associated with chronic alcohol abuse. BMJ Case Reports . 2013;2013 doi: 10.1136/bcr-2012-008263. PubMed DOI PMC

Shibuya N., La Fontaine J., Frania S. J. Alcohol-induced neuroarthropathy in the foot: a case series and review of literature. The Journal of Foot and Ankle Surgery . 2008;47(2):118–124. doi: 10.1053/j.jfas.2007.12.009. PubMed DOI

Brownrigg J. R., Davey J., Holt P. J., et al. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia . 2012;55(11):2906–2912. doi: 10.1007/s00125-012-2673-3. PubMed DOI

Wukich D. K., Raspovic K. M., Suder N. C. Prevalence of peripheral arterial disease in patients with diabetic Charcot neuroarthropathy. The Journal of Foot and Ankle Surgery . 2016;55(4):727–731. doi: 10.1053/j.jfas.2016.01.051. PubMed DOI

Meloni M., Ahluwalia R., Bellia A., et al. The neuro-ischaemic Charcot foot: prevalence, characteristics and severity of peripheral arterial disease in acute Charcot neuro-arthropathy. Journal of Clinical Medicine . 2022;11(21):p. 6230. doi: 10.3390/jcm11216230. PubMed DOI PMC

Sohn M. W., Lee T. A., Stuck R. M., Frykberg R. G., Budiman-Mak E. Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care . 2009;32(5):816–821. doi: 10.2337/dc08-1695. PubMed DOI PMC

Nobrega M. B., Aras R., Netto E. M., et al. Risk factors for Charcot foot. Archives of Endocrinology and Metabolism . 2015;59(3):226–230. doi: 10.1590/2359-3997000000042. PubMed DOI

Thiruvoipati T., Kielhorn C. E., Armstrong E. J. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes. World Journal of Diabetes . 2015;6(7):961–969. doi: 10.4239/wjd.v6.i7.961. PubMed DOI PMC

Tesfaye S., Boulton A. J., Dyck P. J., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care . 2010;33(10):2285–2293. doi: 10.2337/dc10-1303. PubMed DOI PMC

Rosskopf A. B., Loupatatzis C., Pfirrmann C. W. A., Boni T., Berli M. C. The Charcot foot: a pictorial review. Insights Into Imaging . 2019;10(1):p. 77. doi: 10.1186/s13244-019-0768-9. PubMed DOI PMC